Compare UiPath Inc (PATH) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Teladoc Health Inc — how do they compare? UiPath Inc trades at $13.57 (market cap $7.26B), while Teladoc Health Inc trades at $6.09 (market cap $1.14B). The key difference: UiPath Inc is far larger — about 6.4× Teladoc Health Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| PATH | TDOC | |
|---|---|---|
Market Cap | $7.26B | $1.14B |
Sector | Technology | Health |
52-Week High | $19.29 | $9.72 |
52-Week Low | $9.38 | $4.47 |
Enterprise Value | $6.05B | $1.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) is trading at $14.01, down 7.77% in the last 24 hours amid mixed technical signals and earnings volatility. The stock shows improving fundamentals with revenue growing from $892M in 2022 to $1.43B in 2025, though profitability remains negative with a -$73.69M net income. Recent Q2 2026 earnings beat expectations but guidance concerns triggered a selloff, with technical indicators showing bearish momentum despite oversold RSI conditions.
PATH presents a turnaround opportunity with strong revenue growth and improving margins, but faces execution risks in competitive AI automation. Analyst consensus targets $17.38 (24% upside) despite cautious ratings, with institutional interest growing. Key risks include sustained profitability challenges and AI competition, while positive cash flow trends and strategic positioning in enterprise automation offer long-term potential.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Analyst consensus is a hold with a $8.88 price target, while recent news highlights leadership changes and ongoing legal investigations.
The outlook is cautious; while valuation ratios like P/S of 0.45 and EV/EBITDA of 6.5 appear attractive, persistent losses and negative ROE of -12.99% pose risks. Upside depends on profitability improvements under new CFO Michael Grasher, but investor sentiment is tempered by weak earnings and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
